Verona Pharma PLC (VRNA) reports significant sales growth for Ohtuvayre, but faces increased expenses and competition in the COPD market.

Q3 2024 Earnings Call Transcript November 4, 2024 Verona Pharma plc beats earnings expectations. Reported EPS is $-0.08819, ...

Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more ...

Q3 2024 Earnings Conference Call November 4, 2024 9:00 AM ETCompany ParticipantsDavid Zaccardelli - President and ...

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Verona Pharma (VRNA – Research Report), boosting the price target to ...

H.C. Wainwright raised the firm’s price target on Verona Pharma (VRNA) to $42 from $36 and keeps a Buy rating on the shares post the Q3 ...

Dupixent – which is due for a verdict from the FDA as a COPD therapy later this month – was cleared for adults with uncontrolled COPD with raised blood eosinophils, while Ohtuvayre can be used ...

Highlights:,Ohtuvayre™ generates $5.6 million in net sales in its first seven weeks, signaling a strong market entry.,October ...

Verona Pharma (NASDAQ:VRNA) is scheduled to announce Q3 earnings results on Monday, November 4th, before market open. The consensus EPS Estimate is -$0.41 and the consensus Revenue Estimate is $2.01M.

At the heart of Verona Pharma’s recent success is Ohtuvayre (ensifentrine), a revolutionary treatment for chronic obstructive pulmonary disease (COPD). According to David Zaccardelli, the President ...

Tens of thousands of U.S. citizens live in the Israeli-occupied territory, on opposing sides of an entrenched conflict, where neither Palestinians nor Israelis have much enthusiasm for Kamala ...

Oct. 24, 2024 — Lithium-sulfur batteries have never lived up to their potential as the next generation of renewable batteries for electric vehicles and other devices. But mechanical engineers ...